Literature DB >> 19208615

Should sildenafil be available over the counter?

Naomi Rubin1, Kevan Wylie.   

Abstract

INTRODUCTION: This article considers the process of re-classification of prescription drugs from prescription-only medications to over-the-counter (OTC) prescription drugs. SOURCES OF DATA: The recent change in classification for emergency contraception and simvastatin is explored in detail with similarities and differences being considered for a similar argument to be made for sildenafil. AREAS OF AGREEMENT: The benefits for patients, physicians and other healthcare professionals are considered in detail. AREAS OF CONTROVERSY: We raise concerns about recently developed and existing patient group directions that, although extensive in their assessment, may omit to identify significant contributory factors which would necessitate appropriate medical intervention. GROWING POINTS: While the decision for re-classification to OTC would depend on a number of factors, we argue that, with the proviso of proper assessments being made, sildenafil should be made available as an OTC medication. AREAS TIMELY FOR DEVELOPING RESEARCH: The safety and use of OTC medications for erectile dysfunction at a time when many first line prescription agents are reaching generic status.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208615     DOI: 10.1093/bmb/ldp001

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  2 in total

1.  Pharmacist supply of sildenafil: pharmacists' experiences and perceptions on training and tools for supply.

Authors:  Rhiannon Braund; Kaushalya Ratnayake; Katie Tong; Jackie Song; Stephen Chai; Natalie Gauld
Journal:  Int J Clin Pharm       Date:  2018-03-31

2.  A multicenter, randomized, open-labeled, parallel group trial of sildenafil in alcohol-associated erectile dysfunction: the impact on psychosocial outcomes.

Authors:  Alexander M Ponizovsky; Lev Averbuch; Ira Radomislensky; Alexander Grinshpoon
Journal:  Int J Environ Res Public Health       Date:  2009-09-23       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.